<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04622007</url>
  </required_header>
  <id_info>
    <org_study_id>eFT508-0011</org_study_id>
    <nct_id>NCT04622007</nct_id>
  </id_info>
  <brief_title>Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy</brief_title>
  <acronym>KICKSTART</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Effector Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Effector Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, double-blind, placebo-controlled study will evaluate the efficacy and safety of&#xD;
      tomivosertib in subjects with NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With&#xD;
      Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or&#xD;
      When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects will be randomized 1:1 to receive tomivosertib or matching placebo in combination with pembrolizumab. In Cohort A, subjects who have initiated pembrolizumab as a single agent and experienced initial radiographic progression will receive blinded investigational product (IP, tomivosertib or matching placebo) in addition to pembrolizumab. In Cohort B, subjects will receive blinded IP (tomivosertib or matching placebo) in combination with pembrolizumab as first line therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>In both cohorts, investigational product (IP, tomivosertib or placebo) will be blinded and pembrolizumab will be open label.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To characterize the progression-free survival (PFS) of tomivosertib when added to pembrolizumab as a first-line treatment; and</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To characterize the PFS of tomivosertib when added to pembrolizumab after first radiographic progression on pembrolizumab monotherapy.</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the PFS of tomivosertib when added to pembrolizumab in Cohorts A and B combined;</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PFS of tomivosertib when added to pembrolizumab as a first-line treatment in subjects with NSCLC;</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PFS of tomivosertib when added to pembrolizumab after first radiographic progression on pembrolizumab monotherapy;</measure>
    <time_frame>2 years</time_frame>
    <description>Defined as the time from randomization to the first occurrence of disease progression as assessed by the Investigator using RECIST 1.1 or death from any cause, whichever occurs earlier. Objective response per RECIST 1.1, as assessed by the BIRC</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Tomi + Current Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert will receive tomivosertib in addition to pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pbo + Current Pembro</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects who have initiated pembrolizumab as a single agent and in accordance with the package insert, will receive matching placebo in addition to pembrolizumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 Tomi + Pembro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will initiate pembrolizumab as first-line therapy and receive tomivosertib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pbo + Pembro</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will initiate pembrolizumab as first-line therapy and receive matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tomivosertib</intervention_name>
    <description>Tomivosertib (eFT508) will be taken at 100 mg twice daily (bid) with meals</description>
    <arm_group_label>B1 Tomi + Pembro</arm_group_label>
    <arm_group_label>Tomi + Current Pembro</arm_group_label>
    <other_name>eFT508</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Subjects will initiate or continue to receive pembrolizumab at either 200 mg intravenously (IV) at a frequency of every 3 weeks or 400 mg IV at a frequency of every 6 weeks.</description>
    <arm_group_label>B1 Tomi + Pembro</arm_group_label>
    <arm_group_label>Pbo + Current Pembro</arm_group_label>
    <arm_group_label>Pbo + Pembro</arm_group_label>
    <arm_group_label>Tomi + Current Pembro</arm_group_label>
    <other_name>Keytruda®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria for Cohort A: Subjects who meet all of the following criteria will&#xD;
             be eligible to participate in Cohort A of the study:&#xD;
&#xD;
             1. Have initiated first-line therapy for NSCLC with pembrolizumab and satisfy the&#xD;
             following:&#xD;
&#xD;
               -  Have tumor PD-L1 ≥50% by 22C3 IHC;&#xD;
&#xD;
               -  Are judged by the Principal Investigator as tolerating pembrolizumab monotherapy;&#xD;
                  and&#xD;
&#xD;
               -  Have been on pembrolizumab for at least 3 months (measured from actual first dose&#xD;
                  date to first dose date of the current study) and the most recent scans are the&#xD;
                  first scans to objectively demonstrate Progressive Disease per RECIST 1.1.&#xD;
&#xD;
          -  The first scan conducted a minimum of 21 days after first dose of anti-PD-(L)1 therapy&#xD;
             must have shown either SD, PR, or CR (ie, not Progressive Disease) per RECIST 1.1; and&#xD;
&#xD;
          -  The 2 most recent scans (including 1 demonstrating Progressive Disease) are available&#xD;
             to be reviewed.&#xD;
&#xD;
          -  Inclusion Criterion for Cohort B&#xD;
&#xD;
        Subjects who meet the following criterion will be eligible to participate in Cohort B of&#xD;
        the study:&#xD;
&#xD;
        1. Are eligible for single-agent pembrolizumab for advanced/metastatic NSCLC in accordance&#xD;
        with the package insert and have tumor PD-L1 ≥50% by 22C3 IHC.&#xD;
&#xD;
          -  Inclusion Criteria for Both Cohorts&#xD;
&#xD;
          -  Subjects must also meet all of the following criteria to be eligible to participate in&#xD;
             the study:&#xD;
&#xD;
               1. Have histologically confirmed NSCLC that is inoperable, locally advanced or&#xD;
                  metastatic (Stage IIIb/IV), and was not treated with chemotherapy in the&#xD;
                  advanced/metastatic setting; Note: Subjects may have received chemotherapy and/or&#xD;
                  anti-PD-(L)1 therapy in the neo/adjuvant setting, provided the last dose of&#xD;
                  therapy was &gt;9 months prior to randomization.&#xD;
&#xD;
               2. Have available at the site a representative formalin-fixed, paraffin-embedded&#xD;
                  tumor specimen that enabled diagnosis of NSCLC in a tissue block (preferred) or&#xD;
                  10 unstained, serial slides, accompanied by an associated pathology report.&#xD;
                  Cytological or fine-needle aspiration samples are not acceptable; Note: If the&#xD;
                  archival tissue is neither sufficient nor available, the subject may still be&#xD;
                  eligible, upon discussion with the Medical Monitor, assuming the subject can&#xD;
                  provide ≥5 unstained, serial slides. Cytological or fine-needle aspiration&#xD;
                  samples are not acceptable.&#xD;
&#xD;
               3. Have provided written informed consent and any authorizations required by local&#xD;
                  law;&#xD;
&#xD;
               4. Are ≥18 years of age;&#xD;
&#xD;
               5. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have received platinum-based chemotherapy or initiated anti-PD-(L)1 therapy with&#xD;
             chemotherapy for locally advanced or metastatic NSCLC; Note: Subjects may have&#xD;
             received chemotherapy and/or anti-PD-(L)1 therapy in the neo/adjuvant setting,&#xD;
             provided the last dose of therapy was &gt;9 months prior to randomization.&#xD;
&#xD;
          2. Have NSCLC with epidermal growth factor receptor or anaplastic lymphoma kinase genomic&#xD;
             tumor aberrations;&#xD;
&#xD;
          3. Have gastrointestinal (GI) disease (eg, gastric or intestinal bypass surgery,&#xD;
             pancreatic enzyme insufficiency, malabsorption syndrome, symptomatic inflammatory&#xD;
             bowel disease, chronic diarrheal illness, and/or bowel obstruction) that may interfere&#xD;
             with drug absorption or with interpretation of GI AEs;&#xD;
&#xD;
          4. Have known symptomatic brain metastases requiring &gt;10 mg/day of prednisone (or its&#xD;
             equivalent). Subjects with previously diagnosed brain metastases are eligible if they&#xD;
             have completed their treatment, have recovered from the acute effects of radiation&#xD;
             therapy or surgery prior to randomization, fulfill the steroid requirement for these&#xD;
             metastases, the 2 most recent serial magnetic resonance imaging (MRI) scans conducted&#xD;
             &gt;28 days apart show no central nervous system progression, and are neurologically&#xD;
             stable and asymptomatic;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Premal Patel, MD, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Effector Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark D</last_name>
    <phone>858-414-4953</phone>
    <email>MDensel@effector.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern Cancer Center</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Meshad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HAL</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Thomas</last_name>
      <phone>602-277-4868</phone>
      <email>theresa.thomas@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Loretta Weir</last_name>
      <phone>(602)277-4868</phone>
      <email>loretta.weir@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Abhimanyu Ghose, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanette Cardenas</last_name>
    </contact>
    <contact_backup>
      <phone>(520)886-0206</phone>
      <email>jeanette.cardenas@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ahmed Abdelaziz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence (cCARE)</name>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <zip>92024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bunnell</last_name>
    </contact>
    <investigator>
      <last_name>Michael Kosmo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pacific Shores Medical Group</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Hamilton, MSc</last_name>
      <phone>562-590-0345</phone>
      <phone_ext>380</phone_ext>
      <email>christinah@pacshoresoncology.com</email>
    </contact>
    <investigator>
      <last_name>Nishan Tchekmedyian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research &amp; Excellence (cCARE)</name>
      <address>
        <city>San Marcos</city>
        <state>California</state>
        <zip>92069</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Bunnell</last_name>
    </contact>
    <investigator>
      <last_name>Michael Kosmo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jesal C. Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers</name>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <zip>34613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Leonard, RN, BSN</last_name>
      <phone>352-364-9401</phone>
    </contact>
    <investigator>
      <last_name>Daniel Kerr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of Brevard</name>
      <address>
        <city>Palm Bay</city>
        <state>Florida</state>
        <zip>32901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Venkat P. Kancharla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Woodlands Medical Specialists, PA</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rami Owera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John B. Amos Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
      <phone>352-364-9401</phone>
    </contact>
    <investigator>
      <last_name>Andrew Pippas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maryland Oncology Hematology, P.A.</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohit Narang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Fogal</last_name>
      <phone>314-362-1518</phone>
      <email>clfogal@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Morgensztern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Broome Oncology</name>
      <address>
        <city>Johnson City</city>
        <state>New York</state>
        <zip>13790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Driguneswar Pinnamaneni</last_name>
    </contact>
    <contact_backup>
      <phone>(607)763-8065</phone>
      <email>epinnamaneni@broomeoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ronald Harris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gabrail Cancer Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Smith, RN</last_name>
      <phone>330-417-8231</phone>
      <email>csmith@gabrailcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Nashat Gabrail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Sholl, RN, BSN</last_name>
      <phone>419-383-4553</phone>
      <email>jill.sholl@utoledo.edu</email>
    </contact>
    <investigator>
      <last_name>Roland Skeel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Willamette Valley Cancer Institute and Research Cente</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roosevelt Anderson</last_name>
      <phone>541-683-5001</phone>
      <email>roosevelt.anderson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Butrynski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - South Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James. VH Uyeki, MI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77702-1449</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Scott A. McKenney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Bedford</name>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <zip>76022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Illum Henrik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Dallas Presbyterian Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kristi J. McIntyre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Baylor Charles A. Sammons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kartik Konduri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denton</name>
      <address>
        <city>Denton</city>
        <state>Texas</state>
        <zip>76201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles V. Kurkul, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Flower Mound</name>
      <address>
        <city>Flower Mound</city>
        <state>Texas</state>
        <zip>75028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Enrique A. Perez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth Cancer Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rachel L. Theriault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Cancer Associates</name>
      <address>
        <city>Harlingen</city>
        <state>Texas</state>
        <zip>78550</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Hernandez</last_name>
      <phone>956-622-4693</phone>
    </contact>
    <investigator>
      <last_name>Todd Shenkenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Guerra, RN</last_name>
      <email>lguerra@oncologyconsultants.com</email>
    </contact>
    <investigator>
      <last_name>Julio Peguero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Memorial City</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muffaddal S. Morkas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Willowbrook</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Henna Malik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - West Texas</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Williams</last_name>
      <phone>432-687-1949</phone>
      <email>mary.williams2@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Pankaj Khandelwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Paris</name>
      <address>
        <city>Paris</city>
        <state>Texas</state>
        <zip>75460-5004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sucharu Prakash, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Plano East</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75075-7787</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos A. Taboada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Donald A. Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Waco</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Fonseca</last_name>
      <phone>254-399-0741</phone>
      <email>laura.fonseca@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Carl Chakmakjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology-Deke Slayton Cancer Center</name>
      <address>
        <city>Webster</city>
        <state>Texas</state>
        <zip>77598-4420</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anish Meerasahib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaudai Kelly</last_name>
      <phone>425-297-5577</phone>
      <email>Shaudai.Valdez@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ajay Kundra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University Cancer Institute</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ross</last_name>
      <phone>304-581-1158</phone>
      <email>carla.ross@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Almubarak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

